Article Type
Changed
Mon, 10/31/2022 - 13:53

Key clinical point: Survival outcomes are unaffected by postoperative opioid use in patients who have undergone hepatectomy or liver transplantation for hepatocellular carcinoma (HCC).

Major finding: Patients who did vs did not receive opioids had no significant difference in overall survival (adjusted hazard ratio [aHR] 1.10; P  =  .478) or recurrence-free survival (aHR 1.15; P  =  .229).

Study details: This retrospective cohort study included 812 patients aged >20 years with HCC who underwent hepatectomy and did (n = 530) or did not (n = 282) receive opioids during the postoperative period.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Yeh PH et al. No association of postoperative opioid usage with long-term surgery outcomes in patients with liver cancer: A population-based retrospective cohort study. Pain. 2022 (Sep 8). Doi: 10.1097/j.pain.0000000000002776

 

Publications
Topics
Sections

Key clinical point: Survival outcomes are unaffected by postoperative opioid use in patients who have undergone hepatectomy or liver transplantation for hepatocellular carcinoma (HCC).

Major finding: Patients who did vs did not receive opioids had no significant difference in overall survival (adjusted hazard ratio [aHR] 1.10; P  =  .478) or recurrence-free survival (aHR 1.15; P  =  .229).

Study details: This retrospective cohort study included 812 patients aged >20 years with HCC who underwent hepatectomy and did (n = 530) or did not (n = 282) receive opioids during the postoperative period.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Yeh PH et al. No association of postoperative opioid usage with long-term surgery outcomes in patients with liver cancer: A population-based retrospective cohort study. Pain. 2022 (Sep 8). Doi: 10.1097/j.pain.0000000000002776

 

Key clinical point: Survival outcomes are unaffected by postoperative opioid use in patients who have undergone hepatectomy or liver transplantation for hepatocellular carcinoma (HCC).

Major finding: Patients who did vs did not receive opioids had no significant difference in overall survival (adjusted hazard ratio [aHR] 1.10; P  =  .478) or recurrence-free survival (aHR 1.15; P  =  .229).

Study details: This retrospective cohort study included 812 patients aged >20 years with HCC who underwent hepatectomy and did (n = 530) or did not (n = 282) receive opioids during the postoperative period.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Yeh PH et al. No association of postoperative opioid usage with long-term surgery outcomes in patients with liver cancer: A population-based retrospective cohort study. Pain. 2022 (Sep 8). Doi: 10.1097/j.pain.0000000000002776

 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: HCC November 2022
Gate On Date
Fri, 08/27/2021 - 19:45
Un-Gate On Date
Fri, 08/27/2021 - 19:45
Use ProPublica
CFC Schedule Remove Status
Fri, 08/27/2021 - 19:45
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
332967.1
Activity ID
83146
Product Name
Clinical Edge Journal Scan
Product ID
124
Supporter Name /ID
Exact Sciences Corporate [ 6025 ]